Pioglitazone promotes preadipocyte proliferation by downregulating p16(Ink4a)

Biochem Biophys Res Commun. 2011 Jul 29;411(2):375-80. doi: 10.1016/j.bbrc.2011.06.152. Epub 2011 Jun 29.

Abstract

Pioglitazone, a synthetic ligand of peroxisome proliferator-activated receptor (PPAR)γ, causes preadipocyte proliferation through a mechanism which still remains elusive. Here, to address the mechanism, we investigated the effects of PPARγ and pioglitazone on the kinetics of cyclin-dependent kinase inhibitors, especially with p16(Ink4a) (p16) centered, by employing 3T3-L1 preadipocytes. Pioglitazone promoted preadipocyte proliferation by increasing S and G(2)/M cell-cycle entry, which was accompanied by decreased p16 mRNA expression. PPARγ overexpression along with the luciferase reporter assay confirmed that PPARγ was crucial for the downregulation of p16 mRNA transcription, and that the action was augmented by pioglitazone. Thus, pioglitazone exerted cell-cycle dependent promoting effect on preadipocyte proliferation, of which mechanisms include p16-downregulation through PPARγ.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3-L1 Cells
  • Adipocytes / cytology
  • Adipocytes / drug effects*
  • Animals
  • Cell Cycle / drug effects
  • Cell Proliferation / drug effects*
  • Cyclin-Dependent Kinase Inhibitor p16 / antagonists & inhibitors*
  • Cyclin-Dependent Kinase Inhibitor p16 / genetics
  • Down-Regulation
  • Hypoglycemic Agents / pharmacology*
  • Mice
  • PPAR gamma / agonists
  • PPAR gamma / metabolism
  • Pioglitazone
  • RNA, Messenger / antagonists & inhibitors
  • RNA, Messenger / biosynthesis
  • Thiazolidinediones / pharmacology*
  • Transcription, Genetic / drug effects

Substances

  • Cyclin-Dependent Kinase Inhibitor p16
  • Hypoglycemic Agents
  • PPAR gamma
  • RNA, Messenger
  • Thiazolidinediones
  • Pioglitazone